Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the effectiveness of SPI-1620 in
combination with docetaxel in patients with advanced biliary cancer.